Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Account Payables (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Change in Account Payables for 5 consecutive years, with -$4.3 million as the latest value for Q3 2024.

  • Quarterly Change in Account Payables fell 251.88% to -$4.3 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$6.4 million through Sep 2024, down 228.7% year-over-year, with the annual reading at -$2.4 million for FY2023, 220.36% down from the prior year.
  • Change in Account Payables for Q3 2024 was -$4.3 million at Relay Therapeutics, down from $3.2 million in the prior quarter.
  • The five-year high for Change in Account Payables was $4.6 million in Q3 2022, with the low at -$5.4 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$46210.5, with a median of -$56000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 828.46% in 2022, while the deepest fall reached 5950.0% in 2022.
  • Over 5 years, Change in Account Payables stood at $1.3 million in 2020, then soared by 89.63% to $2.4 million in 2021, then fell by 19.15% to $2.0 million in 2022, then crashed by 373.21% to -$5.4 million in 2023, then grew by 19.99% to -$4.3 million in 2024.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$4.3 million, $3.2 million, and $102000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.